Mutations of the Pre-core Region of Hepatite B Virus (HBV) (HEPATITEB)

Centre Hospitalier Universitaire, Amiens

Status: Completed

Conditions: Hepatitis B Virus

Study type: Observational

Funder types: Other

Identifiers

NCT03625258

AOL09-DR-CASTELAIN

Details and patient eligibility

About

Hepatitis B virus (HBV) infection constitutes a major public health threat worldwide. A total of 92 patients with HBeAg-negative chronic hepatitis B infection were recruited at Amiens University Hospital. The diagnostic workup included a physical examination.In conclusion, the study results confirmed that the HBV DNA level is associated with liver fibrosis status and that HBV viral load is strongly correlated with BCP and PC mutations, and it demonstrated that the impaired base pairing 1858-1896 mutations at the base of the bulge in the e encapsidation signal is independently associated with high serum HBV DNA levels.

Full description

The progression of liver disease in hepatitis B virus (HBV) infection is fostered by active virus replication. Mutations in the basal core promoter (BCP) and precore (PC) regions of the HBV genome are known to have an impact on viral replication. The aim of the present study was to assess the correlation of mutation profiles in the BCP and PC regions with the viral load in HBeAgnegative chronically infected patients. The HBV genotype, BCP/PC mutations, serum HBV DNA levels, and associated serological markers were analyzed in 92 HBeAgnegative chronically infected patients.

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients included will be chronic carriers (HBsAg + for more than 6 months) of HBV, with detectable serum viral load greater than or equal to 100 IU / mL, included in the queue followed by Drs. Dominique Capron and Eric N'Guyen-Khac.

These patients will not be on anti-HBV treatment.

Exclusion criteria

• Patients under 18 years old
• Patients with their hepatitis B
• Patients with HBV viral load undetectable or less than 100 IU / mL.
• Immunosuppressive treatments such as corticosteroids or other
• The co-infection with the hepatitis C and / or HIV virus
• Patients with cancer